Toward Pharmacologic Modification of Joint Damage in Osteoarthritis

Editorials1 June 1995Toward Pharmacologic Modification of Joint Damage in OsteoarthritisKenneth D. Brandt, MDKenneth D. Brandt, MDIndiana University School of Medicine, Indianapolis, IN 46202-5103Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-122-11-199506010-00011 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Osteoarthritis is the most common joint disease, and osteoarthritis of the knee is the most common cause of chronic disability among elderly persons in the United States. Current pharmacologic therapy is based chiefly on the use of nonsteroidal anti-inflammatory drugs (NSAIDs) and analgesics that, in most cases, are only moderately effective. The elderly—those at greatest risk for osteoarthritis—are also at greatest risk for serious NSAID side effects such as gastroenteropathy. Joint replacement is often effective but is generally recommended only after years of pain and disability.Because of the limitations of current therapy, interest has arisen in agents that are ...References1. Lequesne M, Brandt K, Bellamy N, Moskowitz R, Menkes CJ, Pelletier JP, et al. Guidelines for testing slow-acting and disease-modifying drugs in osteoarthritis. J Rheumatol Suppl. 1994; 41:65-71. Google Scholar2. Burkhardt D, Ghosh P. Laboratory evaluation of antirheumatic drugs as potential chondroprotective agents. Semin Arthritis Rheum. 1987; 17:3-34. Google Scholar3. Howell DS, Altman RD, Pelletier JP. Disease modifying anti-rheumatic drugs: current status of their application in animal models of osteoarthritis. In: Kuettner K, Goldberg V, eds. New Horizons in Osteoarthritis. Chicago: American Academy of Orthopedic Surgeons; (In press). Google Scholar4. Di Pasquale G. Pharmacologic control of cartilage degeneration in osteoarthritis. In: Woessner JF, Howell DS, eds. Joint Cartilage Degradation: Basic and Clinical Aspects. New York: Marcel Dekker; 1993:475-501. Google Scholar5. Pelletier JP, Martel-Pelletier J. Protective effects of prophylactic treatment with tiaprofenic acid or intraarticular corticosteroids on osteoarthritic lesions in the experimental dog model. J Rheumatol Suppl. 1991; 27:127-30. Google Scholar6. Howell DS, Pita JC, Muller FJ, Manicourt DH, Altman RD. Treatment of osteoarthritis with tiaprofenic acid: biochemical and histological protection against cartilage breakdown in the Pond-Nuki canine model. J Rheumatol Suppl. 1991; 27:138-42. Google Scholar7. Pelletier JP, Fernandes J, Mineau F, Otterness I, Martel-Pelletier J. Tenidap markedly reduces the progression of lesions in experimental osteoarthritis: inhibition of metalloproteinase synthesis. Osteoarthritis and Cartilage. 1994; 2(Suppl 1):58. Google Scholar8. Sipe JD, Bartle LM, Loose LD. Modification of proinflammatory cytokine production by the antirheumatic agents tenidap and naproxen.A possible correlate with clinical acute phase response. J Immunol. 1992; 148:480-4. Google Scholar9. Busch SJ, Martin GA, Barnhart RL, Mano M, Cardin AD, Jackson RL. Trans-repressor activity of nuclear glycosaminoglycans on Fos and Jun/AP-1 oncoprotein-mediated transcription. J Cell Biol. 1992; 116:31-42. Google Scholar10. Smith MM, Ghosh P, Numata Y, Bansal MK. The effects of orally administered calcium pentosan sulfate on inflammation and cartilage degradation produced in rabbit joints by intraarticular injection of a hyaluronate-polylysine complex. Arthritis Rheum. 1994; 37:125-36. Google Scholar11. Rejholec V. Long-term studies of antiosteoarthritic drugs: an assessment. Semin Arthritis Rheum. 1987; 17(2 Suppl 1):35-53. Google Scholar12. Yu LP Jr, Smith GN Jr, Brandt KD, Myers SL, O'Connor BL, Brandt DA. Reduction of the severity of canine osteoarthritis by prophylactic treatment with oral doxycycline. Arthritis Rheum. 1992; 35:1150-9. Google Scholar13. Greenwald RA. Treatment of destructive arthritis disorders with MMP inhibitors. Potential role of tetracyclines. In: Greenwald RA, Golub LM, eds. Inhibition of Matrix Metalloproteinases: Therapeutic Potential. Ann N Y Acad Sci. 1994; 732:181-98. Google Scholar14. Golub LM, Ramamurthy NS, McNamara TF, Greenwald RA, Kawai P, Hamaski T, et al. Method to reduce connective tissue destruction. United States Patent 5,258,371. 3 Nov 1993. Google Scholar15. Dougados M, Gueguen A, Nguyen M, Thiesce A, Listrat V, Jacob L, et al. Longitudinal radiologic evaluation of osteoarthritis of the knee. J Rheumatol. 1992; 19:378-84. Google Scholar16. Buckland-Wright JC, Macfarlane DG. Radio-anatomic assessment of therapeutic outcome in osteoarthritis. In: Kuettner K, Goldberg V, eds. New Horizons in Osteoarthritis. Chicago: American Academy of Orthopedic Surgeons; (In press). Google Scholar17. Spector TD, Hart DJ, Doyle DV. Incidence and progression of osteoarthritis in women with unilateral knee disease in the general population: the effect of obesity. Ann Rheum Dis. 1994; 53:565-8. Google Scholar18. Haynes RB, Wang E, Da Mota Gomes M. A critical review of interventions to improve compliance with prescribed medications. Patient Education Counseling. 1987; 10:155-66. Google Scholar19. Tilley B, Alarcon G, Heyse S, Trentham D, Neuner R, Clegg D, et al. Minocycline for treatment of rheumatoid arthritis: the MIRA trial experience. Arthritis Rheum. 1993; 36(Suppl 9):S46. Google Scholar20. Lang JM. The use of a run-in to enhance compliance. Stat Med. 1990; 9:87-95. Google Scholar Author, Article, and Disclosure InformationAuthors: Kenneth D. Brandt, MDAffiliations: Indiana University School of Medicine, Indianapolis, IN 46202-5103Corresponding Author: Kenneth D. Brandt, MD, Rheumatology Division, Indiana University School of Medicine, 541 Clinical Drive, Room 492, Indianapolis, IN 46202-5103.Grant Support: In part by grant AR 20582 from the National Institute of Arthritis and Musculoskeletal Diseases. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byPharmacotherapy of Pain in Older Adults: NonopioidThe efficacy and tolerability of glucosamine sulfate in the treatment of knee osteoarthritis: A randomized, double-blind, placebo-controlled trialAnthraquinone-2,6-Disulfonic Acid as a Disease-modifying Osteoarthritis DrugIn Vitro Effects of Chondroitin SulfatePharmacotherapy of Pain in Older AdultsTetracyclines for the treatment of rheumatoid arthritisNovel strategies for the treatment of osteoarthritisOsteoarthritis: Update on Pathology, Pathogenesis and TreatmentSYNOVIAL FLUID MARKERS IN OSTEOARTHRITISOsteoarthritis: A reviewRecent developments in the treatment of osteoarthritisTetracyclines Inhibit Connective Tissue Breakdown by Multiple Non-Antimicrobial MechanismsEffect of an Inhibitor of Matrix Metalloproteinases on Spontaneous Osteoarthritis in Guinea PigsManagement of Osteoarthritis in Older AdultsGlucosamine Sulfate for Osteoarthritis7 Pharmacotherapy and osteoarthritisEffects of diacerhein in an accelerated canine model of osteoarthritisOsteoarthritisMonitoring collagen degradation in patients with arthritis. The search for suitable surrogatesPreferences in the management of osteoarthritis of the hip and knee: Results of a survey of community-based rheumatologists in the United StatesA model of osteoarthritis and a potential new therapyGuidelines for the medical management of osteoarthritis 1 June 1995Volume 122, Issue 11Page: 874-875KeywordsAnalgesicsAnimal modelsCartilageClinical trialsDrug metabolismDrugsKneesNSAIDsOral administrationOsteoarthritis ePublished: 15 August 2000 Issue Published: 1 June 1995 Copyright & PermissionsCopyright © 1995 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...